inhibitors and modulators, and therefore can mitigate diseases related to the CXCR4-CXCL12 pathway. We have designed and synthesized a series of 2,5-diamino and 2,5-dianilinomethyl pyridine derivatives as potential CXCR4 antagonists. Thirteen compounds have an effective concentration (EC) of 100 nM or less in a binding affinity assay and nine of these have at least 75% inhibition of invasion in Matrigel binding
CXCR4及其同源
配体CXCL12已与多种途径相关,例如癌症转移,炎症,HIV-1增殖和自身免疫性疾病。小分子已显示出作为CXCR4
抑制剂和调节剂的潜力,因此可以缓解与CXCR4-CXCL12途径有关的疾病。我们已经设计和合成了一系列2,5-二
氨基和2,5-
二苯胺基甲基
吡啶衍生物作为潜在的CXCR4拮抗剂。在结合亲和力测定中有13种化合物的有效浓度(
EC)为100 nM或更小,其中9种在基质胶结合测定中具有至少75%的浸润抑制作用。化合物3l,7f,7j和7p进行角叉菜胶爪
水肿试验时,炎症反应最小。总之,这些化合物显示出作为CXCR4拮抗剂的潜力。